Interferon in the treatment of cutaneous T-cell lymphoma.
Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.
Olsen
Elise A
EA
Division of Dermatology, CTCL Clinic and Research Center, Duke University, Durham, North Carolina 27710, USA. olsen001@mc.duke.edu
D001682:Biological Availability; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D009367:Neoplasm Staging; D011379:Prognosis; D011994:Recombinant Proteins; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins